


The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:


Listing of The Claims:

1. (Currently Amended): A compound comprising ~~Compounds of~~ formula (I):



wherein

A is a hydrogen atom; a group of formula $-C(=NR^4)NH_2$, wherein R^4 is a hydrogen atom, a heteroalkyl, hetero-aralkyl, heterocycloalkyl, heteroalkylcycloalkyl, hydroxy or alkyloxy group or is, together with one of the radicals R^1 , part of a 5- or 6-membered heteroaryl or heterocycloalkyl ring; a group of formula $-NHC(=NR^4)NH_2$; or has one of the following structures:



Ar^1 is an aryl, aralkyl, heteroaryl or heteroaralkyl group,

Ar² is an aryl, aralkyl, heteroaryl or heteroaralkyl group,

the radicals R¹ are, each independently of any other(s), a hydroxy group, a C₁-C₄alkyloxy group, an amino group, a C₁-C₄alkylamino group, a C₁-C₄-dialkylamino group, a cyano group or a halogen atom;

the radicals R², each independently of any other(s), are a hydroxy group, a C₁-C₄alkyloxy group, an amino group, a C₁-C₄alkylamino group, a C₁-C₄-dialkylamino group, a cyano group or a halogen atom;

R³ is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical;

G is a glycosyl group;

X is a group of formula NR⁵, O, CONR⁵, NR⁵CO, CH₂NR⁵, S, SO, SO₂, SO₂NH, NHSO₂, PO₂NH, NHPO₂, CH₂, CHMe or CO, wherein R⁵ is a hydrogen atom, a C₁-C₄alkyl, C₁-C₄-heteroalkyl, C₇-C₁₂aralkyl or C₆-C₁₂heteroaralkyl group;

Y is a group of formula CONR⁶, COCONR⁶, NR⁶, O, NR⁶CO, S, SO, SO₂, SO₂NH, NHSO₂, PO₂NH, NHPO₂, CH₂, CHMe or CO, wherein R⁶ is a hydrogen atom, a C₁-C₄alkyl, C₁-C₄-heteroalkyl or C₇-C₁₂aralkyl group;

n is 0, 1, 2, 3 or 4, and

m is 0, 1, 2, 3 or 4,

or a pharmacologically acceptable salt, solvate, hydrate or pharmacologically acceptable formulation thereof; there being excluded compounds in which Y is a group of formula CONR⁶ and R³ is a group of formula -CHR⁷-CO-NR⁸R⁹, R⁷, R⁸ and R⁹ being, each independently of the others, a hydrogen atom, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroaralkyl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl, alkylcyclo-alkyl,

heteroalkylcycloalkyl or aryl group, or R⁸ and R⁹ together are part of a heterocycloalkyl or heteroaryl ring system; there furthermore being excluded compounds wherein Y is a group of formula CO and R³ is a group of formula -NR¹⁰-CHR⁷-CO-NR⁸R⁹, R⁷, R⁸, R⁹ and R¹⁰ being, each independently of the others, a hydrogen atom, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroaralkyl, heteroaryl, alkylcyclo-alkyl, heteroalkyl-cycloalkyl, aralkyl, cycloalkyl, heterocycloalkyl or aryl group, or R⁸ and R⁹ and/or R⁷ and R¹⁰ together are part of a heterocycloalkyl or heteroaryl ring system.

2. (Original): Compounds according to claim 1, wherein A is a group of formula – C(=NH)NH₂.

3. (Currently Amended): Compounds according to claim 1 ~~or 2~~, wherein Ar¹ is a phenyl or heteroaryl group having 5, 6, 7, 8, 9 or 10 carbon ring atoms and 1, 2, 3 or 4 ring hetero atoms selected from O, S and N.

4. (Currently Amended): Compounds according to claim 1 ~~or 2~~, wherein Ar¹ is a phenyl group to which the groups A and X are bonded in positions meta to one another.

5. (Currently Amended): Compounds according to ~~one of claims 1, 2, 3 or 4~~, wherein Ar² is a phenyl group.

6. (Currently Amended): Compounds according to ~~one of claims 1, 2, 3, 4 or 5~~, wherein X is an NH group.

7. (Currently Amended): Compounds according to ~~one of claims 1, 3, 4, 5 or 6~~, wherein n is 0 or 1.

8. (Currently Amended): Compounds according to ~~one of claims 1, 2, 3, 4, 5, 6 or 7~~, wherein R¹ is a hydroxy group.

9. (Currently Amended): Compounds according to ~~one of claims 1, 2, 3, 4, 5, 6, 7 or 8~~, wherein m is 0 or 1.

10. (Currently Amended): Compounds according to ~~one of~~ claims 1, 2, 3, 4, 5, 6, 7, 8 or 9, wherein Y is a group of formula CONH.

11. (Currently Amended): Compounds according to ~~one of~~ claims 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein R³ is a group of formula -U-V-W, wherein U is an optionally substituted C₆-C₁₀aryl group or an optionally substituted hetero-aryl group containing from 5 to 10 ring atoms and 1, 2, 3 or 4 hetero atoms selected from O, S and N; V is a direct bond, an oxygen atom, a sulphur atom, a group of formula NR¹¹ (R¹¹ being a hydrogen atom, a C₁-C₄alkyl, C₁-C₄heteroalkyl, C₇-C₁₂aralkyl or C₆-C₁₂heteroaralkyl group), CO, SO, SO₂ or SO₂NH, and W is a hydrogen atom, an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcyclo-alkyl, aralkyl, heteroalkylcycloalkyl, heterocyclo-alkyl or heteroaralkyl radical.

12. (Original): Compounds according to claim 11, wherein U is an optionally substituted phenyl group.

13. (Currently Amended): Compounds according to claim 11 ~~or 12~~, wherein V is a direct bond or a carbonyl group.

14. (Currently Amended): Compounds according to claim 11, ~~12 or 13~~, wherein W is a C₁-C₄alkyl group, a C₁-C₄heteroalkyl group, an optionally substituted phenyl group, an optionally substituted C₃-C₇cycloalkyl group, an optionally substituted heterocycloalkyl group having 3-7 ring atoms and 1, 2 or 3 hetero atoms (selected from O, S and N) or an optionally substituted heteroaryl group having 5 or 6 ring atoms and 1, 2, 3 or 4 hetero atoms selected from O, S and N.

15. (Currently Amended): Pharmaceutical compositions comprising a compound according to claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 ~~or 14~~ and, optionally, carrier substances and/or adjuvants.

16. (Currently Amended): ~~Use of a compound or of a pharmaceutical composition according to one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 in~~ A method for inhibiting factor Xa by administering a compound of claim 1.

17. (Currently Amended): ~~Use of a compound or of a pharmaceutical composition according to one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 in~~ A method for the treatment and/or prevention of thromboembolic conditions, arterial restenosis, septicaemia, cancer, acute inflammation or other conditions mediated by factor Xa activity comprising administering a compound of claim 1.

18. (Currently Amended): ~~Use of a compound or of a pharmaceutical composition according to one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15~~ A method for utilisation preventing or reducing complications relating to thromboembolic conditions in vascular surgery comprising administering a compound of claim 1 prior to, during or following said surgery.